Obesity promotes B16BL6 melanoma cell invasiveness and Snai1 expression by Kushiro, Kyoko
  
 
 
 
 
 
 
 
Copyright 
by 
Kyoko Kushiro 
2012 
 
 
The Thesis Committee for Kyoko Kushiro 
Certifies that this is the approved version of the following thesis: 
 
 
Obesity Promotes B16BL6 Melanoma Cell Invasiveness and Snai1 
Expression 
 
 
 
 
 
 
 
 
APPROVED BY 
SUPERVISING COMMITTEE: 
 
 
 
Nomelí P. Núñez 
Stephen D. Hursting 
 
Supervisor: 
 Obesity Promotes B16BL6 Melanoma Cell Invasiveness and Snai1 
Expression 
 
 
BY 
Kyoko Kushiro, B.A. 
 
 
Thesis 
Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Master of Arts 
 
 
The University of Texas at Austin 
May 2012 
DEDICATION 
 
This thesis is dedicated to my family - loving parents and awesome brothers - who have 
always trusted and encouraged me in all that I do.  I would also like to dedicate this work 
to my dear husband and his wonderful family who fully supported me with their love and 
patience. 
 
 v 
ACKNOWLEDGEMENTS 
 
I would like to thank Dr. Nomelí P. Núñez for being my PI and giving me a place 
in his lab to pursue my degree. I would also like to thank Dr. Stephen D. Hursting for his 
expertise and advice. I would further like to thank my lab mates Renee E. Stubbins, Amy 
W. Wong, Dr. Jina Hong, post-doctorate fellow Dr. Valerie B. Holcomb, and 
undergraduate students for making lab time a great experience.  Lastly, I would like to 
thank the great friends I’ve made in Austin who kept me grounded throughout this 
process.  I sincerely thank everyone for being a part of my life as they have helped me 
become the happy person I am today! 
 vi 
ABSTRACT 
 
Obesity Promotes B16BL6 Melanoma Cell Invasiveness and Snai1 
Expression 
 
Kyoko Kushiro, M.A. 
The University of Texas at Austin, 2012 
 
Supervisor: Nomelí P. Núñez 
 
Malignant melanoma is cancer arising from melanocytes that have acquired the ability to 
metastasize and colonize secondary organs such as the lungs, liver, and brain.  According 
to the Melanoma Research Foundation, malignant melanoma is the most rapidly 
increasing type of cancer with an annual incidence increase of ~ 4% despite the 
therapeutic and medical breakthroughs in cancer treatment.  Melanoma is the most 
common cancer in young adults ages 20-30, and it is the leading cause of cancer death in 
females ages 25-30.  Non-modifiable risk factors include age, gender, and inherited 
predisposition to moles.  As for modifiable risk factors, exposure to UV rays from the sun 
is well-established, but obesity has recently emerged as a factor through recent 
epidemiological and animal studies.  Our results showed that obesity modulates the 
expression of the transcription factor Snai1, which has been shown to be a key gene in 
the regulation of the Epithelial-to-Mesenchymal Transition (EMT). Serum from obese 
 vii 
ob/ob mice, as well as conditioned media from 3T3L1 adipocytes, increased the invasive 
ability of melanoma cells and the expression of the transcription factor Snai1.   Yet, the 
cytokine IL-6 may not be a critical component of obesity-mediated B16BL6 melanoma 
cell invasiveness. 
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CHAPTER 1: INTRODUCTION 
Malignant melanoma accounts for 75% of deaths associated with skin cancer due 
to its aggressive metastasis to vital organs such as the brain and lungs.  Obesity has 
recently been suggested to be a factor that modulates the metastatic ability of melanoma 
cells, though the mechanism is still unclear. Thus, in order to better understand the 
biology by which melanomas metastasize, we investigated obesity’s effect on the 
metastatic cell phenotype and on the expression of key genes known to affect the 
Epithelial-to-Mesenchymal Transition (EMT), such as Snai1. 
CANCER 
The disease of cancer was first described back in 3000 BC in the Edwin Smith 
Papyrus that contained descriptions of patient cases regarding tumors or ulcers of the 
breast that exhibited “crab-like” projections (1).  Compared to the past where the disease 
was stated to “[have] no treatment”, we have come a long way in the field of cancer 
therapy.  However, even though we have made great advances in cancer research that 
have led to effective preventative and clinical interventions, much remains to be done in 
order to eradicate cancer. 
According to the National Cancer Institute, cancer is a disease that results from 
the accumulation of various genetic mutations in a cell that gives the cell the ability to 
proliferate and grow uncontrollably (2).  According to the World Health Organization 
(WHO), despite the vast improvement in early detection and effective treatments for 
several cancers, cancer is still the leading cause of human mortality with about 7.6 
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million deaths a year; this translates to about 13% of all causes of deaths globally (3).  
Quite daunting is the projection that the global cancer-related death count will increase to 
over 11 million worldwide by 2030 if we maintain this trajectory.  Similarly, medical 
costs associated with cancer have nearly doubled from the $24.7 billion/yr back in 1987 
to $48.1 billion/yr during the years of 2001-2005 in the United States (4).  According to 
WHO, about 30% of cancers can be prevented with dietary interventions, proper physical 
activity, and less use of tobacco (3). 
SKIN 
Averaging a surface area of 21 square feet, the human body is surrounded by a 
protective barrier called the skin.  The skin is indeed the body’s largest organ that is 
composed of numerous cell types that regulate important body functions such as heat 
regulation.  Its primary function, however, is to act as a barrier against harmful 
substances such as microorganisms, chemicals, and ultraviolet light (5).  As a 
consequence, the skin is constantly exposed to numerous agents making skin cancer the 
most common form of human cancer (6-8). 
The skin is composed of many cells and many layers. One type of cell that makes 
up the outer-most layer of the skin called the epidermis is the melanocyte that produces 
the pigment melanin to protect the skin from the damaging effects of UV light (Figure 
1.1) (9).  Melanocytes originate from melanoblasts that arise from the neuroectoderm to 
colonize and populate the surface ectoderm of the skin (10).  These cells produce melanin 
in vesicles that can be deposited into surrounding cells such as keratinocytes; in these 
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keratinocytes, melanin forms a protective cap over the nucleus to shield the DNA from 
the damaging effects of UV rays (11).  
 
 
Figure 1.1 The Skin adapted from http://www.web-books.com/eLibrary/Medicine/Phy 
siology/Skin/Skin.htm. The skin is composed of various layers and cells. Melanocytes 
reside in the outermost epidermis of the skin.  
 
MELANOMA 
Melanoma is cancer arising from transformed melanocytes.  Even though 
malignant melanoma represents only 4% of all skin cancers, it is the most deadly, 
accounting for 75% of deaths from skin cancer (12).  In 2003, approximately 54,000 new 
cases of cutaneous melanoma were diagnosed and 7,600 people died from this disease in 
the United States (13).  In 2009, the numbers increased to 121,840 and 8,650, 
respectively (14).  According to the Melanoma Research Foundation, malignant 
melanoma is one of the most rapidly increasing types of cancer with an annual incidence 
increase of ~ 4%.  Melanoma is the most common cancer in young adults ages 20-30, and 
it is the leading cause of cancer death in females ages 25-30 (8). 
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MELANOMA PROGRESSION 
It is thought that melanoma progression follows the Clark model of tumorigenesis 
where a collection of clonally inheritable events generates a cancer cell with metastatic 
capabilities that can enter the deeper dermis. That is, a melanocyte transitions into a 
benign nevus (mole) before acquiring migratory properties to become classified as 
malignant.  For a melanoma cell to become invasive, they must acquire “vertical growth-
phase” (VGP) properties rather than remaining at the “radial growth-phase” (RGP), 
which had previously only allowed them to grow in the epidermis (Figure 1.2) (15).  
There are a number of known molecular changes that are most commonly found in 
human melanomas and not in melanocytes. These include activating mutations of BRAF 
(16), silencing mutations of E-cadherin (17), and adverse mutations of p16/ARF (18).  
Thus, the pathways involved in melanoma progression are numerous and complex, and 
require further investigation. 
 
 
Figure 1.2 Melanoma Progression adapted from (19). Melanocytes accumulate genetic 
changes that allow the progression from benign nevus to metastatic melanoma. 
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MELANOMA TREATMENT 
Surgery resulting in excision of the melanoma is the most successful method of 
treatment. Yet, malignant melanomas gradually obtain the ability to invade, migrate, and 
metastasize to the lungs, liver, bone, and brain.  These highly inoperable secondary 
tumors are responsible for the high mortality rate of melanoma cancer patients. 
Alarmingly, 94% of stage IV melanoma patients with detectable metastasis die from 
melanoma within 5 years of diagnosis (20).  Current therapeutic treatments, including 
standard chemotherapy treatments, high doses of interferon-α-2b, or regimens of high 
doses of IL-2 therapy against melanoma have largely been unfruitful and with dangerous 
side effects (21, 22).  The average duration of benefits from these therapies is usually in 
the range of months. Therefore, further work is needed to better understand factors and 
genes that may be used as targets to prevent melanoma metastasis.  Furthermore, these 
dire results stress the importance of not only early diagnosis, but also of melanoma 
prevention. 
RISK FACTORS 
Interestingly, a positive family history accounts for 5-12% of all melanoma cases, 
where having one first-degree relative with melanoma indicates a 2-fold increase in life-
time risk. This finding foreshadows the importance of key gene mutations in the 
development of this disease.  The CDKN2A gene mutation is the most common gene 
mutation found in families with multiple melanoma patients (23, 24).  This gene encodes 
two proteins considered to be tumor suppressors of melanomas, INK4A/p16 and ARF, 
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which have been shown to inhibit improper cell cycle progression and cell proliferation 
(25, 26).  
Though inherited genetic mutations account for a large number of melanoma 
cases, epidemiological studies have also unearthed several risk factors for melanoma: 1) 
race and skin type, 2) propensity to develop moles throughout life, and 3) excessive 
exposure to sunlight.  Hereditary family traits such as fair skin that freckles or burns 
easily without tanning are considered risk factors, regardless of family history of 
melanoma incidence. Caucasians have the highest incidence of melanoma while people 
possessing darker skin, and thus, more melanin, such as Asians and African Americans 
are less susceptible (27). 
Regarding sun exposure, studies show that intense and intermittent exposure to 
the sun is more detrimental and may increase melanoma incidence compared to 
cumulative exposure (28, 29).  One theory is that consistent cumulative exposure may 
“prime” the DNA-damage response program in the cell to be more active, allowing for a 
better checking system that can fight against malignant transformation of melanocytes 
into cancer cells.  However, other studies show that sun burns in early childhood can also 
increase the risk of melanoma (30, 31).  Animal studies show that even though UV light 
cannot induce melanoma in mice by itself, it is able to promote melanoma development 
when combined with chemical skin carcinogens such as DMBA (32-34).  Sun exposure, 
though there is much debate about the mechanism by which it increases melanoma risk, 
is clearly an established risk factor for melanoma. 
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OBESITY AND MELANOMAS 
Over 60% of the U.S. population is considered overweight or obese (35).  Obesity 
is an increasing concern as it can lead to numerous human disorders such as 
cardiovascular diseases and the metabolic syndrome; recently, obesity has also been 
classified as a risk factor for numerous cancers (36). Epidemiological studies show that 
obesity is a risk factor for melanoma: obesity increases the risk of developing 
subcutaneous melanoma  (37) as well as the risk of developing malignant melanoma (38). 
The mechanism by which obesity affects melanoma, however, is not known.  The 
objective of our study was to determine how obesity increases the invasive ability of 
melanomas. Obesity may provide factors that promote a more mesenchymal cell 
phenotype; thus, our specific objective was to determine if obesity affects the expression 
of genes associated with EMT.  
Animal studies show that obesity promotes melanoma tumor progression and 
metastasis.  Pandey et al. showed that diet-induced obesity promoted the growth of 
melanoma tumors (39).  Mori et al. showed that genetically obese mice (ob/ob leptin-
deficient and db/db leptin receptor deficient) developed a higher number of B16BL6 
pulmonary metastases than lean control mice (40).  Mori et al. also showed that the 
retention time of B16BL6 cells tagged with luciferase was increased in the lungs of obese 
mice compared to control lean mice.  Evidence suggests that obesity promotes tumor 
development by inducing a pro-cancerous microenvironment by increasing systemic 
levels of growth and inflammatory factors (41).  This inflammatory environment has 
been hypothesized to be responsible for increasing cancer risk in obese individuals (42, 
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43).  In Chapter 2 of this thesis, we focused on determining the effect of systemic factors 
found in the serum of genetically obese ob/ob mice on their ability to modulate the 
mesenchymal phenotype and metastatic abilities of melanoma cells. 
The cancer microenvironment can be comprised of cancer-associated fibroblasts 
(FACs), macrophages (TAMs), and adipocytes (44-46).   It is feasible that these non-
cancer cells can promote melanoma progression.  In Chapter 3 of this thesis, we 
determined if adipocyte media affected the aggressiveness of B16BL6 melanoma cells.  
The adipocytes can produce factors such as the cytokine Interleukin 6 (IL-6), which can 
affect cancer progression (47).  Thus, Chapter 3 also assessed the role of IL-6 in 
adipocyte media-induced invasiveness of melanomas.   
EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) 
The Epithelial-to-Mesenchymal Transition (EMT) is a developmental program 
whereby an epithelial-type cell acquires a mesenchymal phenotype that allows it to 
acquire migratory and invasive abilities necessary in the various steps of cancer 
progression (Figure 1.3).  The EMT program is often characterized by the aberrant 
activation of transcription factors including Snai1, Slug, Twist, and TGF-β1. These 
transcription factors collectively help inhibit cell-to-cell adhesion that keeps cells 
anchored to each other.  They do this by down-regulating anchorage proteins such as E-
cadherin and increasing the expression of mesenchymal markers such as Vimentin (48-
50).  This program is often activated during embryogenesis as the epithelia need to be 
highly plastic in processes such as organogenesis and gastrulation (Type 1 EMT); EMT 
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also normally occurs in adulthood most prominently during fibroblasts/mesenchymal cell 
recruitment in wound healing (Type 2 EMT).  However, it can be activated in an 
abnormal manner during cancer progression, namely metastasis (Type 3 EMT) (51). We 
will discuss EMT in the context of cancer metastasis in this thesis. 
 
 
Figure 1.3 Epithelial to Mesenchymal Transition (EMT). During EMT, epithelial-type 
cells acquire genetic changes such as increased expression of Snai1 and Twist that lead to 
decreased expression of proteins such as E-cadherin and Kiss1. These changes promote a 
mesenchymal-type phenotype. 
 
In cancer progression, the process of metastasis is one of the six hallmarks of 
cancer, coined by Weinberg et al. back in 2000 and again in their updated review in 2011 
(52, 53).  It is widely accepted that, for successful metastasis to occur, a cell must acquire 
EMT properties to convert itself from a benign cell to a malignant cell. Others have 
identified EMT as a major determinant of melanoma metastasis in cancer patients (54). 
Key molecular changes that are commonly studied in melanomas in association with their 
function in EMT include B-raf, Wnt5A, and TGF-β/SMAD (55-58).  These genes may 
cooperatively increase cell plasticity associated with the EMT phenotype.  On the other 
hand, these genes may down-regulate metastasis suppressor genes such as Kiss1, which 
has been shown to inhibit melanoma metastasis (59).  In the present study, we determined 
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the effects of obesity on EMT and on the expression of genes associated with this 
phenotype, such as Snai1 and Kiss1. 
SNAI1 
Snai1 is a transcription factor identified to be important in EMT and the 
metastasis of melanoma (60, 61).  Snai1 was discovered to be involved in EMT because 
mice and fly embryos that are homozygous recessive for Snai1 fail to gastrulate properly 
due to defects in neural crest closure which requires functional EMT (62, 63). Snai1 
belongs to the snail superfamily of zinc-finger transcription factors that recognizes E-
boxes on promoter regions using its C-terminal DNA-binding and nuclear localization 
domain; currently, several hundred strong binding E-box clusters and potential targets in 
the genome have been identified (64, 65). Its mode of action involves gene repression 
using the conserved SNAG N-terminal domain in vertebrates (66). 
Snai1 is a key regulator of EMT (67, 68). The transcription factor Snai1 is an 
important regulator of metastasis because it down-regulates the expression of E-cadherin 
and other proteins that are involved in cell-to-cell adhesion (69, 70). Furthermore, an 
inverse correlation between Snai1 and E-cadherin has previously been reported in 
melanoma (71).  Others have shown that Snai1 repression of E-cadherin requires Histone 
Deacetylase (HDAC) activity, specifically that of HDAC 1 and 2 which deacetylates 
Histones H3 and H4 at the E-cadherin promoter region in conjunction with the co-
repressor mSin3A (72).   High levels of Snai1 promote tumor invasion by decreasing the 
adhesive ability of the cancer cells; in humans, Snai1 expression is associated with distant 
metastasis and tumor recurrence (73, 74).   
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Aberrant Snai1 expression has also been linked to the up-regulation of several 
mesenchymal genes even though it is a transcriptional repressor.  Genes up-regulated by 
Snai1 expression include mesenchymal genes such as vimentin, fibronectin, Wnt-5A, and 
delta-EF1 (75, 76) .  It is likely that the up-regulation of these genes is an indirect effect 
of Snai1’s ability to repress the expression of their inhibitors. Many of these genes 
promote EMT; namely, delta-EF1 is a transcriptional repressor of E-cadherin, and Wnt-
5A up-regulation has been linked to the down-regulation of important melanoma 
metastasis suppressors such as Kiss1.  Other genes up-regulated by Snai1 expression 
include MMP9, a protein that can degrade extracellular matrix proteins to allow cancer 
cells to escape into the blood or invade secondary tissues in order to establish metastases 
(77, 78). Thus, the diversity of Snai1 gene targets makes Snai1 a very important regulator 
of cancer progression by affecting EMT. 
In the literature, numerous complex signaling circuits have been shown to 
regulate the expression of Snai1, such as the phosphatidylinositol 3-kinase (PI3-K), 
mitogen-activated protein kinases (MAPKs), glycogen synthase kinase 3-beta (GSK-3β) 
and the NF-κB pathway (79). Specifically, NF-κB can bind to the promoter region and 
up-regulate the expression of human Snai1; similarly, the B-raf pathway that is often 
mutated in melanoma cells can feed into the NF-κB pathway and increase Snai1 
expression (55, 80). The well-studied TGF-β pathway has also been shown to up-regulate 
the synthesis of Snai1 in various cancer cells, including the highly metastatic human 
A375 melanoma cell line (81).   
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Chapters 2 and 3 of this thesis investigate the effect of systemic factors on Snai1 
expression. Circulating factors associated with inflammation and obesity have previously 
been linked to the increased expression of Snai1.  TNF-α is one such factor that has been 
shown to affect the expression and stability of Snai1.  Wu et al. showed that TNF-α 
induces a NF-κB-mediated Snai1 stabilization through its ability to induce CSN2 [COP9 
signalosome (CSN) complex component] expression. CSN2 prevents the phosphorylation 
of Snai1 by GSK-3β, which increases the stability of Snai1; by blocking phosphorylation 
of Snai1, the ubiquitin-mediated degradation of  Snai1 is prevented (82). We note that 
phosphorylation is a key mechanism that regulates Snai1 expression because it dictates 
Snai1’s cellular localization in the cytosol or nucleus.  Others show that upon 
phosphorylation of a Ser-rich sequence adjacent to the protein’s nuclear export sequence 
(NES), Snai1 undergoes a conformational change that allows better interaction with the 
CRM1 transporter that facilitates nuclear export of Snai1 (83).  TNF-α can also activate 
Akt, which ultimately activate NF-κB resulting in the up-regulation of Snai1 (84).  
Lastly, TNF-α can also increase the stabilization of Snai1 via the Wnt/β-catenin pathway 
by suppressing GSK-3β activity (85). 
Pertinent to our study, the cytokine Interleukin 6 (IL-6) has recently emerged as a 
possible contributor of Snai1 expression; thus, it is thought to be an important player in 
the progression of numerous cancers, including melanomas.  IL-6 is a cytokine that can 
elicit both a pro-inflammatory or anti-inflammatory response in the body.  It is produced 
mainly by macrophages as an immune response, but adipocytes are also able to secrete 
IL-6 (86).  IL-6 is a ligand that binds to its receptor complex, IL-6R alpha and gp130 in 
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target cells.  This complex goes on to activate STAT3 or SHP-2-mediated RAS signaling 
pathways and affects numerous cellular processes (87).  Epidemiological studies show 
that IL-6 is elevated in the serum and adipose tissue of obese patients (88-90). In 
addition, IL-6 is a serological marker for malignant melanoma (91).  Animal studies also 
show that mice inoculated with B16BL6-melanoma exhibited high systemic levels of IL-
6 (92).  Though these findings are correlative, they suggest that IL-6 may play an 
important role in the invasiveness of melanoma.  It is feasible that IL-6 increases the 
aggressiveness of melanomas by promoting a mesenchymal phenotype via genes 
regulated by the NF-kB pathway, such as Snai1 (93).  
Though these findings are currently correlative, cell culture studies have also 
assessed the effect of IL-6 on cancer cells. Interestingly, IL-6 has been implicated as both 
an inhibitor and an enhancer of cell phenotypes such as cell growth in cancer cells (94, 
95).  In some cases, others have shown that IL-6 is capable of switching from being an 
inhibitor to a stimulator of proliferation when the tumor itself begins to produce it in an 
autocrine manner (96).  In accordance with this finding, others show that some human 
malignant melanoma cell lines endogenously produce detectable levels of IL-6 in an 
autocrine fashion (97).  Thus, IL-6 may be an important obesity-associated cytokine that 
leads to exacerbated melanoma metastasis. 
IL-6 has been shown to increase the expression of Snai1, and consequently EMT, 
in some cancers (98, 99).  Even though the study by Sullivan et al. showed that Snai1 
induction by IL-6 was not as drastic as the induction by TNF-α, we cannot disregard the 
finding that IL-6 may modulate EMT.  We also note a relationship between TNF-α and 
 14 
IL-6  because TNF-α is a strong inducer of NF-κB, which in turn can increase the 
expression of IL-6 in some cells (100).  IL-6 may indirectly induce NF-κB activation by 
activating the PI3K/Akt/NF-κB pathway where the NF-κB inactivating IκB is degraded 
through IKK stimulation (101).  Thus, IL-6 and TNF-α may be having a cooperative 
function in stimulating the expression of Snai1 via NF-κB. Thus, Chapters 2 and 3 of this 
thesis investigate the effect of obese serum and IL-6 on the expression of Snai1 in 
B16BL6 melanoma cells. 
KISS 1 
Kiss1 has been identified as a suppressor of melanoma metastasis (102).  The 
Kiss1 gene was discovered to be localized on chromosome 1, and its expression was 
shown to inhibit the metastatic ability of human melanoma cells   (103).  The Kiss1 
receptor GPR54 was also shown to inhibit the metastatic ability of B16BL6 melanoma 
cells (104).  Thus, the Kiss1 signaling pathway seems capable of inhibiting melanoma 
metastasis.   
Kiss1 is a secreted protein that is processed into peptides of different lengths 
termed kisspeptins (KPs) (105).  Others show that KPs can be cleaved by Matrix 
Metalloproteinases (MMPs), which abolish the ability of these peptides to induce focal 
adhesions to prevent invasion (106). Studies also suggest that Kiss1 affects the 
metastases of cancer cells by decreasing the expression of MMPs, such as MMP9 (78, 
107).  
In terms of cancer prognosis, high levels of Kiss1 in human melanoma samples 
strongly correlate with a positive prognosis and low levels with a worse prognosis.  This 
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underlines the importance of Kiss1 in melanomas because in other cancers such as breast 
cancer or bladder cancer, the expression of Kiss1 does not always correlate with a 
positive outcome (108, 109).  In melanomas, others show that Kiss1 mRNA expression is 
reduced by 50% in primary melanomas exceeding 4mm (110). Patients with melanoma 
tumors of this size have a rapid drop in 5-year survival rate (111). Shirasaki et al. showed 
that both primary melanoma tumors greater than 4mm deep that have gained the ability to 
invade and metastatic melanomas have significantly less Kiss1 compared to primary non-
invasive melanomas (110, 112).   Thus, Kiss1 appears to be a good prognostic marker of 
melanoma progression.  
SUMMARY & PERSPECTIVES  
With few effective treatment options available, malignant melanoma is a 
formidable cancer that is currently the fifth most common cancer in men and women (6).  
Cancer patients with a diagnosis of metastatic melanoma survive, on average, 
approximately 6-9 months (113).  Therefore, it is crucial that we increase our knowledge 
of the mechanism by which melanomas metastasize, so that better therapies for the 
prevention and treatment of melanoma metastasis can be developed.  Obesity is prevalent 
in our society, and the study herein will contribute to our understanding of how obesity 
may affect the metastatic ability of melanomas. 
Chapter 2 will determine the effect of obesity on the invasive ability of B16BL6 
melanoma cells and on EMT genes. 
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Chapter 3 will investigate the effects of adipocyte conditioned media and IL-6 on 
B16BL6 cell invasion and Snai1 expression. 
Chapter 4 will provide an overall discussion and future directions for this thesis 
project. 
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CHAPTER 2: OBESITY PROMOTES A MESENCHYMAL CELL PHENOTYPE IN 
B16BL6 MELANOMA CELLS 
ABSTRACT 
In 2009, malignant melanoma was responsible for approximately 9,000 deaths in 
the United States. These deaths are often associated with aggressive metastasis to 
secondary sites such as the lungs. Epidemiological and animal studies suggest that 
obesity is a risk factor for melanoma. Others have shown that B16BL6 melanoma cells 
metastasize more aggressively in obese ob/ob than in lean mice. However, the 
mechanism by which obesity promotes B16BL6 melanoma metastasis in ob/ob mice has 
not been identified. In the present study, we used serum obtained from control and ob/ob 
leptin-deficient obese mice to determine if obese serum increases the aggressive 
phenotype of melanoma cells. Results showed that ob/ob serum has higher levels of 
resistin, insulin, tPAI1, IL-6, TNF-α, and MCP-1 compared to control serum. We showed 
that ob/ob serum increases the invasive ability of B16BL6 melanomas. To understand the 
mechanism by which ob/ob serum increases the invasive ability of melanomas, we 
determined the effect of ob/ob and control serum on genes associated with the Epithelial-
to-Mesenchymal Transition (EMT). Cancer cells with a mesenchymal phenotype have a 
higher metastatic ability. Snai1 and Twist are genes that are strongly associated with 
EMT and metastasis of melanomas. Our results showed that ob/ob serum increased the 
expression of Snai1 and Twist. Moreover, ob/ob serum increased MMP9 activity and 
decreased the expression of E-cadherin and the metastasis suppressor gene Kiss1. In 
summary, our results suggest that obesity may increase the metastatic ability of 
melanoma by promoting a mesenchymal cell phenotype. 
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INTRODUCTION 
Epidemiological and animal studies suggest that obesity is a risk factor for 
melanoma (37-38, 40). Studies by Dennis et al. showed that obesity increases the risk of 
developing subcutaneous melanoma (37). Moreover, Samanic et al. showed that obesity 
increases the risk of developing malignant melanoma (38). In animal studies, Mori et al. 
demonstrated that obesity promotes pulmonary metastasis of B16BL6 melanoma in obese 
ob/ob mice (40). However, the mechanism by which obesity promotes melanoma 
metastasis is not thoroughly known.  
Ob/ob mice were used as our model of obesity. These mice are leptin-deficient 
and are grossly overweight due to hyperphagia (abnormally increased appetite and food 
consumption); they also exhibit hyperglycemia and severe insulin resistance (114). 
Interestingly, ob/ob mice have been recognized to have lower incidence of cancers such 
as pulmonary and breast cancer (115). In regards to melanoma progression, studies have 
shown conflicting results in ob/ob mice.  Some have observed no difference in B16BL6 
melanoma growth rate when cells are injected orthotopically (40). Others show that 
melanoma cells grow faster when injected subcutaneously in ob/ob mice; still others, 
however, show that both growth rate and metastasis from subcutaneous B16BL6 cell 
injection are more inhibited in ob/ob mice than control lean siblings (116).  This 
resistance to metastasis, though not fully explained, was attributed to increased 
immunocompetence observed as a more acute proliferative response by splenic 
lymphocytes from ob/ob mice towards a T-cell mitogen compared to the response by the 
lumphocytes from control mice.  It is possible, however, that the discrepancy is due to the 
over-abundance of subcutaneous WAT (white adipose tissue) in these ob/ob mice, which 
could be a confounding factor when studying subcutaneous B16BL6 melanoma tumor 
growth and subsequent metastasis. 
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In this ob/ob mouse model, intravenous (i.v.) injection of B16BL6 melanoma 
cells has been used previously to study experimental metastasis (40). This approach 
overcomes the issue of excess subcutaneous WAT that one may encounter with typical 
spontaneous metastasis models that require subcutaneous tumor cell injections.  The 
experimental metastasis model also bypasses the need to remove the primary tumor after 
it reaches a certain size because metastasis usually develops in these animals at a much 
later stage than what is humanely allowed.  It is true that this method limits the study of 
important early steps of metastasis including intravasation, which is one of the rate-
limiting steps of metastasis (117). Yet, the experimental metastasis model still allows 
researcher to study the later stages of metastasis that occur after the cancer cells have 
invaded the bloodstream.  The same study by Zijlstra et al. shows that the establishment 
and growth of micrometastases at the secondary organ is also an important rate-limiting 
step of metastasis for some cancers (117).  Others have supported the view that the early 
steps in metastasis may not be as important as the steps of extravasation and post-
extravasation growth of the individual cancer cell in contributing to the inefficiency in 
metastasis (118-120). Similarly, though some have found a positive correlation between 
the number of circulating cancer cells and poor prognosis, others have found no 
connection between the two (121-124). This suggests that it is critical to investigate the 
steps in melanoma metastasis after extravasation using these B16BL6 melanoma cells in 
ob/ob mice, which can be more accurately observed in an experimental metastasis model 
such as in our study. 
Obesity may increase the metastatic ability of melanoma cells by promoting a 
mesenchymal cell phenotype. Studies show that cancer cells with a mesenchymal 
phenotype have a higher ability to metastasize (125). The transcription factors Snai1 and 
Twist are genes that promote the Epithelial-to-Mesenchymal Transition (EMT) (48, 126). 
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Moreover, Snai1 and Twist have been shown to increase the ability of cancer cells to 
migrate, invade and metastasize (127). Furthermore, overexpression of Snai1 and Twist 
increases cell motility and leads to a significant loss of cell-to-cell adhesion (128). The 
mesenchymal phenotype is also associated with higher expression of Matrix 
Metalloproteinases (MMPs) such as MMP9 (129).  MMPs play a key role in the 
metastatic cascade, because they allow cancer cells to degrade the extracellular matrix 
(ECM), and thus, allow the cancer cells to invade the basement membrane from where 
cancer cells can eventually metastasize to secondary sites (78). 
Alternatively, obesity may promote melanoma metastasis by simultaneously 
leading to a decrease in the expression of genes known to inhibit metastasis. Metastasis 
suppressor genes encode proteins that have the ability to hinder the establishment of 
metastases (130). Metastasis suppressor genes, such as Kiss1, have the ability to inhibit 
the metastatic ability of melanomas (131). Thus, it is feasible that obesity increases the 
metastatic ability of melanomas by increasing the expression of pro-metastatic genes 
such as Snai1 and Twist and also by decreasing the expression of genes that inhibit 
melanoma metastasis, such as Kiss1. 
In the current study, we determined the effects of control and obese serum on the 
invasiveness of B16BL6 melanoma cells. Results showed that ob/ob serum increased the 
ability of B16BL6 melanoma to invade. The higher invasive ability of melanoma was 
associated with increased expression of Snai1, Twist, and MMP9. Furthermore, ob/ob 
serum increased the expression of Snai1 in the nucleus and down-regulated E-cadherin 
expression at the cell membrane of B16BL6 cells. Ob/ob serum also increased MMP9 
activity. Additionally, ob/ob serum decreased the expression of the metastasis suppressor 
gene Kiss1. Overall, our study suggests that obesity may increase the aggressiveness of 
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melanomas by promoting a mesenchymal cell phenotype and by down-regulating the 
expression of the metastasis suppressor gene Kiss1. 
MATERIALS AND METHODS 
Cancer cells and cell culture reagents 
The highly metastatic B16BL6 melanoma cells were kindly provided by Dr. Isiah J. 
Fidler, University of Texas at MD Anderson, Houston TX. The non-metastatic B16F1 
melanoma cells were purchased from American Type Culture Collection (ATCC, 
Chicago, IL). They were maintained in Dulbecco’s modified minimum essential medium 
(Invitrogen, Carlsbad, CA), pH 7.4, containing 10% heat-inactivated fetal bovine serum 
(Invitrogen) and 1% antibiotic-antimycotic solution (CellGro, Manassas, VA).  The cells 
were grown at 37°C in a humidified atmosphere of 5% CO2.   For cell culture studies, 
B16BL6 cells were treated with either 5% ob/ob mice serum or 5% ob/+ heterozygous 
control mice serum. Serums from mice for each group (control or ob/ob) were pooled 
together after the serum analysis was completed. 
Obese ob/ob mice 
All animal procedures and methods employed in our study was approved by the Animal 
Care and Use Committee at the University of Texas at Austin. Pathogen free male ob/ob 
and ob/+ heterozygous control C57BL/6J mice were purchased from The Jackson 
Laboratory (JAX, Bar Harbor, ME) at 6-8 weeks old. They were housed according to 
National Institutes of Health (NIH) guidelines (National Research Council, 1996). They 
were singly housed and maintained on water and a chow diet (Research Diets, New 
Brunswick, NJ) for 15 weeks (n=12). We measured body weight, food consumption, and 
liquid consumption on a weekly basis. After 15 weeks on the diet, mice were euthanized 
using CO2 and blood was drawn by cardiac puncture before cervical dislocation was 
 22 
performed on each mice. The blood was allowed to coagulate at room temperature for 30 
mins. Serum was collected and frozen in liquid nitrogen.  Liver and visceral adipose 
tissues were similarly collected and flashfrozen in liquid nitrogen for RNA analysis at the 
time of killing. Both tissue and serum were stored at -80°C until analyzed. 
Body composition analyses in mice 
Body composition was determined in non-anesthetized mice using an EchoMRI 
Composition Analyzer system (Echo Medical Systems, Houston, TX) as instructed by the 
manufacturer. Percent body fat was determined at 10 weeks into the study (n=12). 
Blood glucose levels 
To determine if ob/ob mice were hyperglycemic compared to control mice, we measured 
blood glucose level after fasting. At the 8th week of the study, mice were fasted for 7hrs 
and their blood glucose levels were determined using a Glucometer Elite (Bayer, Elkhart, 
IN) (n=12). 
Glucose Tolerance Test (GTT) 
To determine the effect of obesity on glucose clearance, we performed the GTT assay. 
Briefly, mice were fasted for 14 hrs and then injected with 20% glucose in PBS 
intraperitoneally. Then, a razor blade was used to make a small cut at the tail vein of each 
mouse and glucose was measured in the blood using a Glucometer Elite (Bayer, Elkhart, 
IN) at 0, 15, 30, 60, and 120 mins post-injection. GTT was examined at the 9th week of 
the study (n=12). 
Insulin Tolerance Test (ITT)  
The ITT assay tests how efficiently endogenous glucose is cleared from the blood as a 
response to insulin administration. ITT was performed after mice were fasted for 7 hrs. 
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They were then given an intraperitoneal injection of 0.75Ukg
-1
 insulin in PBS (Insulin: 
Sigma Aldrich, St. Louis, MO). A razor blade was used to make a small cut at the tail 
vein of each mouse, and blood glucose was measured using a Glucometer Elite (Bayer, 
Elkhart, IN) at 0, 15, 30, 60, and 120 mins post-injection. Area under the curve (AUC) 
was calculated to determine insulin sensitivity. ITT were examined at the 8th week of the 
study (n=12). 
Serum analysis 
To determine obesity’s effect on systemic factors in the blood, we measured leptin, 
insulin, Interleukin 6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), resistin, tissue 
Plasminogen Activator Inhibitor-1 (tPAI-1), and Monocyte Chemotactic Protein-1 (MCP-
1) in the serum of each mouse at the 10
th
 week of the study.  We measured these factors 
with the Millipore’s Multiplex MAP Mouse Serum Adipokine Panel kit (Millipore, 
Billerica, MA) as instructed by the manufacturer (n=12).  
Invasion assay 
We used the Boyden chamber assay to determine the effects of obese mice sera on the 
ability of B16BL6 melanoma cells to invade (132). Briefly, the top chamber membrane 
was coated with a 1:10 dilution of BD Matrigel
TM
 (BD Biosciences, Becton Drive 
Franklin Lakes, NJ), then, 5x10
4
 B16BL6 melanoma cells were placed in the top chamber 
in serum-free DMEM with 0.1% Bovine Serum Albumin (BSA). The lower chamber was 
filled with DMEM containing 5% ob/ob serum or 5% control serum. Cells were allowed 
to migrate from the top side towards the bottom side of each camber for 28 hrs. After 28 
hrs, cells that remained on the top side were removed using a Q-tip. Cells that invaded to 
the bottom side were fixed and stained using Siemens Diff-Quick Stain Set (Siemens, 
Malvern, PA). Stained cells were visualized and quantified by microscopy. To determine 
 24 
the average number of cells that migrated for each well, we counted 3 random fields in 
each well at 200x. Each treatment had 3 wells per experiment, with each experiment 
being independently performed three times (n=3). 
Wounding assay 
The wounding assay was used to determine the effects of high and low glucose on the 
ability of B16BL6 melanoma cells to migrate.  This was done to determine if glucose 
levels can affect the ability of these cells to migrate.  Ob/ob mice are hyperglycemic, and 
thus, it is possible that the high glucose levels found in ob/ob mice may affect the 
aggressiveness of melanoma cells to metastasize (133). In the wounding assay, cells are 
plated to 100% confluency and a scratch is drawn in the middle of the plate. The decrease 
in gap distance is measured over time and quantified; the larger the gap distance that 
remains, the less the cells have migrated. Briefly, B16BL6 cells were grown on a 24-well 
plate until they were confluent. Then, cells were grown in FBS-free DMEM overnight. 
The next day, wells were washed twice with PBS and a scratch was drawn on each well 
using a p200 pipette tip. After two more washes with PBS to get rid of cell debris, the 
following cell culture media was added: 1000mg/L glucose DMEM (low glucose) or 
4,500mg/L glucose DMEM (high glucose). Both media was supplemented with 5% FBS.  
Each well was photographed at the time of treatment (0 hr) and after 9 hrs of incubation 
(9 hr) at 40x.  The difference in gap distance was measured (9 hr time point – 0 hr time 
point) to quantify cell motility. The wounding assay was done in the absence of 
mitomycin C; however, the assay was terminated after 9 hrs, which is less time than the 
16-18 hrs needed for B16BL6 cells to double (134). Thus, cell migration is most likely 
not due to changes in cell proliferation. Each experiment was repeated three times with 
each group having 3 wells per experiment (n=3).   
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Quantitative real time PCR (qRT-PCR) 
Total RNA was collected from three replicate of cells that were serum starved overnight 
and then treated with 5% ob/ob serum or 5% control serum for 24 hrs. The RNA was 
extracted using an RNeasy Mini Kit according to the manufacturer’s instructions 
(Qiagen). Using 1 g of RNA for each sample, reverse transcription was performed with 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Primers for 
18S, IL-6, TNF-α, Snai1, Twist, MMP9, and Kiss1 were purchased from Integrated DNA 
Technologies (IDT, Coralville, IA) and were as follows: 18S F: 
GCATGGCCGTTCTTAGTTGGTGGA, B: TCTCGGGTGGCTGAACG-CCA; IL-6 F: 
GCTGGTGACAACCACGGCCT, B: AGCCTCCGACTTGTGAAGTGGT; TNF-α F: 
CTCTTCAAGGGACAAGGCTG, B: CGGACTCCGCAAAGTCTAAG; Snai1 F: 
CACCTCCAGA-CCCACTCAGAT, B: CCTGAGTGGGGTGGGAGCTTCC; Twist F: 
CCACGCTGCCCTCGGA-CAAG, B: CCAGGCCCCCTCCATCCTCC; MMP9 F: 
GCCCACCGTCCTTTCTTGTTGGA, B: GGGAGAGGTGGTTTAGCCGGTG; Kiss1 
F: GCAAGCCTGGGTCTGCAGGG, B: CGACTGC-GGGAGGCACACAG. 
Quantitative RT-PCR was performed with a SYBR GreenER qPCR kit 
(Invitrogen) in a Mastercycler ep Realplex Real-time PCR thermocycler (Eppendorf 
North America, Hauppauge, NY). The relative expression levels of target genes were 
normalized to the housekeeping 18S rRNA. Amplification specificity was confirmed by 
melting curve analysis. Each gene was measured in quadruplicate and the average ΔCt 
was taken from the 3 replicate wells before fold change was calculated using the ΔΔCt 
method. At least three independent sets of samples were performed for each gene (n=3). 
Immunofluorescence Microscopy 
To determine protein localization of Snai1 and E-cadherin, Immunoflurescence 
microscopy was used. Wax pencils were used to mark a closed circle on microscope 
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coverslips.  B16BL6 cells were plated into the circles and allowed to attach for 24 hrs 
before being FBS-starved overnight.  They were subsequently treated with 5% ob/ob 
serum or 5% control serum for 24 hrs.  Cells were washed twice with PBS and fixed in 
4% formalin/PBS for 10 mins.  Then, cells were subsequently washed twice with PBS 
before being stored in PBS at 4°C overnight.  The next day, cells were permeabilized 
with 0.1% Triton-X100/PBS and neutralized with 100uM glycine/PBS, before being 
treated with antibodies against Snai1 or E-cadherin (Cell Signaling, Danvars, MA and 
Santa Cruz Biotechnology Inc., Santa Cruz, CA) and appropriate fluorescently-
conjugated secondary antibodies (Cell Signaling and Abcam, Cambridge, UK) as 
recommended by the manufacturer.  After three washes with 0.2% Tween20 in PBS, cells 
were counterstained with two drops of DAPI/antifade (Millipore) according to the 
manufacturer’s instructions for detection of cellular nuclei.  After 15 mins of incubation, 
coverslips were placed onto microscope slides and sealed with nail polish, and images 
were taken with the Zeiss Axiovert 200 M fluorescent microscope at UT Austin’s ICMB 
Core Facility.  Images of control and experimental cells were acquired under identical 
exposure conditions for comparative analysis (n=3). 
Western blot analysis 
To determine the total protein expression of E-cadherin in B16BL6 cells in response to 
DMEM, control serum or ob/ob serum treatments, western blot analysis was carried out 
on whole cell lysates.  For this purpose, B16BL6 cells were grown to about 70% 
confluency in 10 cm
3
 plates.  Cells were rinsed with PBS and then FBS-starved 
overnight.  Then, cells were treated with control DMEM, 5% control serum, or 5% ob/ob 
serum in DMEM for 24 hrs.  After the various treatments, cells were rinsed twice with 
PBS, trypsinized, and centrifuged at 10,000 rpm for 5 mins at 4°C.  The supernatant was 
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discarded, and the pellets were stored in -80°C overnight.  The next day, cells were 
washed twice with PBS before being lysed in 300uL RIPA buffer (Thermo Scientific, 
Waltham, MA) supplemented with a protease inhibitor cocktail (Roche, South San 
Francisco, CA).  After a 45-min incubation on ice, cells were centrifuged at 10,000 rpm 
for 10 mins at 4°C.  The supernatant was collected and protein concentration was 
measured using the Bradford Assay.  50ug of protein was loaded and run on an SDS-
PAGE gel at 100-150V for 1 hr.  The gel was subsequently transferred to a PMSF 
membrane, blocked in 5% milk, washed numerous times in TBST, and probed for E-
cadherin (Santa Cruz Biotechnology Inc.) and β-actin (Cell Signaling) and appropriate 
HRP-conjugated secondary antibodies (Santa Cruz Biotechnology Inc.) before incubation 
with ECL and film exposure. 
Zymogen gel assay 
To determine MMP9 activity in B16BL6 cells after different treatments, we performed 
the zymogen gel assay.  Briefly, B16BL6 cells were treated with 5% ob/ob serum or 5% 
control serum for 24 hrs.  1.5mL of this media was subsequently collected and 
concentrated using a centrifugal protein concentrator (Millipore). 20uL of protein 
concentrate was mixed with a 2X zymogen loading dye to a final volume of 40uL. This 
sample was loaded onto a zymogen gel (Bio-Rad Laboratories, Hercules, CA) to 
determine MMP9 activity as described previously (135). Three separate assays were 
performed (n=3). 
Statistical analysis 
All experiments were analyzed for significance using the independent Student’s t-test in 
SPSS (PAWS version 18). P-values < 0.05 were considered significant, and all data is 
represented as the mean ± SEM. 
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RESULTS 
Ob/ob mice  
Others have shown that ob/ob mice are hyperglycemic and insulin resistant (114, 136).  
We verified these previous findings.  Final body weights for control mice was 33.73g 
while ob/ob mice had a final body weight of 56.65g (p<0.05).  Results showed that ob/ob 
mice had significantly higher body fat levels than control mice (Figure 2.1A). We also 
showed that ob/ob mice are hyperglycemic and hyperinsulinemic compared to control 
mice (Figure 2.1B, 2.2A). Our results similarly showed that ob/ob mice were insulin 
resistant as determined by the GTT and ITT assay (Figure 2.1C, D). The GTT assay 
measures how quickly injected glucose is cleared from the blood. The ITT assay tests 
how quickly endogenous glucose is cleared from the blood in response to insulin 
administration. Results showed that ob/ob mice cleared blood glucose at a significant 
lower rate than control mice, thus, suggesting that they are indeed insulin resistant 
(p<0.05).     
Adipokine and pro-inflammatory factors in ob/ob mice 
As expected, systemic levels of leptin in ob/ob were undetectable (Figure 2.2A).  
However, other adipokines such as resistin and tPAI-1 were significantly higher in ob/ob 
mice (Figure 2.2A).  In agreement with previous reports, we showed that ob/ob mice 
have higher levels of pro-inflammatory factors; systemic MCP-1, IL-6, and TNF-α were 
significantly higher in ob/ob mice (Figure 2.2B, 2.2C). Additionally, IL-6 and TNF-α 
were elevated in the adipose tissue of ob/ob mice, but only TNFα was elevated in the 
livers of these mice (Figure 2.2D). 
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Ob/ob serum increased the invasiveness of B16BL6 melanoma  
To determine if the factors that increased the metastatic phenotype of B16BL6 melanoma 
cells in ob/ob mice were found in the blood, we determined the ability of serum from 
ob/ob and control mice to affect the invasive ability of melanoma cells in cell culture 
conditions. For this purpose, we tested the effect of ob/ob serum on the ability of 
B16BL6 cells to invade through a Matrigel
TM
-coated chamber compared to control serum 
treatment. Results showed that B16BL6 cells exposed to ob/ob serum were more invasive 
than B16BL6 cells exposed to control serum (Figure 2.3).  
High glucose increased B16BL6 melanoma cell migratory ability 
Evidence suggests that high systemic glucose levels can increase the risk of cancers (133, 
137). Thus, it is possible that high levels of glucose in ob/ob mice can affect the 
metastatic ability of melanoma cells. Using the wounding assay in cell culture conditions, 
we determined the effects of a high-glucose media on the ability of B16BL6 cells to 
migrate compared to low-glucose media.  Results showed that high glucose levels 
increased the ability of B16BL6 cells to migrate compared to low glucose lovels (Figure 
2.4). Thus, it is possible that once the melanoma cells reach the blood, the high levels of 
growth factors (e.g., insulin) and pro-inflammatory factors (e.g., IL-6) in conjunction 
with high glucose levels promote the metastatic ability of melanoma cells. 
Ob/ob serum increases the expression of Snai1, Twist, and MMP9 
To better understand the mechanism by which ob/ob serum affects the invasive 
phenotype of melanomas, we determined the effect of ob/ob serum on the expression of 
genes associated with the Epithelial-to-Mesenchymal Transition (EMT). The 
mesenchymal phenotype in cancer cells is associated with a strong ability of cancer cells 
to invade and metastasize (138). The gene expression of both Snai1 and Twist 
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transcription factors has been established to be strongly associated with the mesenchymal 
phenotype of cancers such as melanomas (56, 139).  To determine if the metastatic ability 
of B16BL6 melanoma cells were associated with the expression levels of Snai1 and 
Twist, we measured their levels in highly metastatic B16BL6 and non-metastatic B16F1 
melanoma cells. Our results showed that Snai1 and Twist were up-regulated while E-
cadherin was down-regulated in highly metastatic B16BL6 cells compared to non-
metastatic B16F1 melanoma cells (Figure 2.5A). To determine if the expression of Snai1 
is modulatable by the presence and absence of serum, we exposed the highly metastatic 
B16BL6 to either no serum or 10% fetal bovine serum for 24 hrs. Results showed that 
Snai1 expression was increased in B16BL6 cells treated with 10% FBS compared to 
FBS-starved cells (Figure 2.5B).  Thus, these results showed that expression of Snai1 can 
be modulated by different serum. 
Next, we exposed the highly metastatic B16BL6 melanoma to ob/ob serum to 
determine if obese sera would increase the expression of Snai1 and Twist. Results 
showed that the ob/ob obese serum significantly increased the expression of both Snai1 
and Twist (Figure 2.5C). Through Immunofluorescence microscopy, we also determined 
that ob/ob serum increased Snai1 expression in the nucleus of B16BL6 cells and 
correspondingly decreased E-cadherin expression at the cell membrane compared to 
control serum (Figure 2.5D).  We confirmed a decrease in total E-cadherin protein 
expression in B16BL6 cells after ob/ob serum treatment (Figure 2.5E).  Thus, we 
showed that ob/ob serum increases Snai1 expression and decreases E-cadherin 
expression, which are hallmarks of EMT (126). 
In some cells, the Matrix Metalloproteinase 9 (MMP9) expression is regulated by 
Snai1 (77). MMP9 allows cancer cells to invade surrounding tissue by degrading the 
extracellular matrix (107). Since ob/ob serum not only increased the ability of melanomas 
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to invade but also up-regulated the expression of Snai1, we expected the obese serum to 
increase the expression of MMP9. Indeed, results showed that ob/ob serum increased the 
expression of MMP9 in B16BL6 cells (Figure 2.5C). Furthermore, ob/ob serum 
modestly increased the amount of active MMP9 compared to control serum (Figure 
2.5F). 
Effects of ob/ob serum on Kiss1 expression 
Alternatively, obesity may increase the ability of melanoma cells to metastasize by 
promoting a mesenchymal phenotype and also by decreasing the expression of genes 
known to inhibit metastasis. Metastasis suppressor genes can slow down or prevent 
metastasis (131). Kiss1 is a metastasis suppressor known to inhibit melanoma metastasis 
(110). Our results showed that ob/ob serum decreased the expression of Kiss1 in B16BL6 
cells (Figure 2.5C). 
Effects of insulin, resistin, and TNF-α on Snai1, Kiss1, and MMP9 expression 
To determine which obesity-related factors found in the serum of ob/ob mice affected the 
expression of Snai1, Kiss1, and MMP9, we treated B16BL6 melanoma cells with purified 
insulin, resistin, and TNF-α to measure the expression levels of these genes. We showed 
that resistin treatment increased Snai1 and MMP9 expression, though not significant, 
while it decreased Kiss1 levels significantly (Figure 2.6A). Insulin treatment up-
regulated MMP9 but decreased Kiss 1 (Figure 2.6B).  Lastly, we showed that Kiss1 
expression decreased in a time-dependent manner after TNF-α (1ng/mL) treatment 
(Figure 2.6C). Thus, these obesity-related factors may additively contribute to the 
modulation of the aggressiveness of B16BL6 melanoma and the EMT phenotype. 
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DISCUSSION 
Consistent with previous reports, we showed that leptin-deficient ob/ob mice exhibit 
numerous obesity-related symptoms such as excess body weight, excess body fat, insulin 
resistance, hyperinsulinemia, and chronic inflammation (114). Moreover, ob/ob mice had 
a local (e.g. adipose and liver tissue) and systemic inflammatory environment as reflected 
by high levels of IL-6, TNF-α, resistin, tPAI-1, and MCP-1 in the serum compared to 
control mice. We also showed that ob/ob mice have higher glucose levels than control 
mice, and that higher glucose levels increased the ability of melanomas to migrate in cell 
culture conditions. Hence, the higher levels of glucose in ob/ob mice may not only meet 
the higher nutritional requirements of melanoma cells, but also increase their ability to 
migrate and invade to secondary sites. Thus, the pro-cancerous environment found in the 
blood of ob/ob mice may allow melanoma cells to enhance their survival and to establish 
metastases in secondary tissue. 
Mori et al. previously showed that B16BL6 melanoma cells established much 
more numerous and grossly larger metastases in the lungs of obese ob/ob mice than in 
control mice (40).  Our results suggest that the serum of obese ob/ob mice may indeed 
increase the metastatic phenotype of melanoma. The invasive ability of a cancer cell is an 
important functional phenotype necessary for successful metastasis (140). Supporting 
Mori el al.’s results, we showed that ob/ob serum increased the invasive ability of 
B16BL6 melanoma cells compared to control serum. To understand the molecular 
mechanisms by which ob/ob serum increased cell invasion, we determined its effect on 
the expression of genes linked to cell invasion and metastasis. In fact, we showed that 
ob/ob serum increased the expression of Snai1 and Twist, genes that are associated with 
the mesenchymal phenotype (68). We focused our attention on these transcription factors 
because they have been shown to modulate EMT and the aggressive phenotype of 
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melanoma cells (60, 71). Melanoma cells with an epithelial phenotype are less aggressive 
than those with a mesenchymal phenotype (54). Cancer cells that transition towards a 
mesenchymal phenotype often lose the expression of cell adhesion proteins that keep the 
cells anchored together and prevent them from breaking away from the primary tumor 
(141). In some cancers, the transcription factors Snai1 and Twist decrease the expression 
of E-cadherin, which is a protein found in the cell membrane that plays a key role in cell 
adhesion: it allows cells within tissues to adhere to each other (142, 143). Our results 
showed that treatment of melanoma cells with ob/ob serum increased nuclear localization 
of Snai1 and decreased the amount of E-cadherin at the cell membrane. 
Factors found in the serum of ob/ob mice such as IL-6 and TNF-α have been 
shown to increase the expression of Snai1 (98, 99). Thus, it is feasible that the pro-
inflammatory environment found in ob/ob mice promotes a mesenchymal phenotype by 
increasing the expression of Snai1 and Twist to affect the metastatic ability of B16BL6.  
Indeed, we showed that resistin and insulin also affected the expression of Snai1 and 
MMP9.  Others have shown that overexpression of Snai1 and Twist can increase both the 
mesenchymal phenotype and the metastatic ability of melanoma cells (56, 60, 128). 
Moreover, Snai1 also increases the expression of MMP9, a protein that can degrade 
extracellular matrix proteins; the degradation of the extracellular matrix proteins may 
allow cancer cells to escape into the blood or invade secondary tissues in order to 
establish metastases (77, 78). In our study, we showed that ob/ob serum increased the 
expression of MMP9 and its activity in B16BL6 melanoma cells, which may explain why 
B16BL6 melanoma cells have a higher invasive ability in the presence of ob/ob serum. 
Besides affecting genes associated with EMT, obese serum may also increase the 
metastatic phenotype of melanoma cells by decreasing the expression of genes known to 
inhibit metastasis.  Metastasis suppressors are genes that have been identified to stop or 
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slow down metastasis (144). In our study, we measured the expression levels of Kiss1, 
which was originally discovered for its ability to suppress the metastatic ability of two 
human melanoma cell lines (103). Studies suggest that one anti-metastatic function of 
Kiss1 may be to decrease the expression of Matrix Metalloproteinases (MMPs), such as 
MMP9 (107, 78). Interestingly, others show that Kiss1 is also down-regulated in cancer 
cells that acquire a mesenchymal phenotype (145). We found that treatment of B16BL6 
melanoma cells with ob/ob serum decreased the expression of Kiss1. Furthermore, we 
showed that both resistin and insulin decreased Kiss1 expression and increased MMP9 
expression in B16BL6 melanoma. Similarly, TNF-α treatment decreased Kiss1 
expression in a time-dependent manner. Thus, systemic obesity-related factors may 
collectively modulate EMT and the aggressive phenotype of melanoma cells. In 
summary, as Figure 2.7 depicts, our results suggest that systemic factors found in the 
blood of ob/ob mice may contribute to increasing the aggressiveness of melanoma cells 
to metastasize by promoting a mesenchymal phenotype and by decreasing the expression 
of the metastasis suppressor gene Kiss1. 
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Figure 2.1 Ob/ob mice.  Mice were given water and food ad lib for 15 weeks. A) Ob/ob 
mice had higher percent body fat and B) higher fasting glucose levels in their blood than 
control mice. Mice were insulin resistant as observed by the C) Glucose Tolerance Test 
(GTT) and D) Insulin Tolerance Test (ITT) assays results (mean ± SEM, n=12 
mice/group, * is p< 0.05) 
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Figure 2.2 Systemic factors in ob/ob mice. Mice were given water and food ad lib for 
15 weeks. At the 10
th
 week of the study, serum was collected and analyzed for circulating 
factors. Ob/ob mice had A) undetectable leptin, higher levels of insulin, t-plasminogen 
activator inhibitor-1 (tPAI-1), resistin, B) Monocyte chemoattractant protein-1 (MCP-1), 
C) Interleukin 6 (IL-6), and Tumor Necrosis Factor alpha (TNF-α) compared to control 
mice (mean ± SEM, n=12 mice/group, * is p< 0.05). At the end of the study, adipose 
tissue and liver were collected and analyzed using qRT-PCR for inflammatory factors. D) 
Ob/ob mice had higher levels of IL-6 and TNF-α in adipose tissue. Ob/ob mice had 
higher levels of TNF-α in the liver; however, IL-6 levels in the liver were similar to those 
of control mice. (mean ± SEM, n=3 mice/group, * is p< 0.05) 
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Figure 2.3 Ob/ob serum increases B16BL6 cell invasion. B16BL6 cells were exposed 
to 5% ob/ob serum or 5% control serum for the invasion assay.  The images shown are 
pictures of cells that invaded during the 24 hour period. Number of B16BL6 cells that 
invaded in the ob/ob and the control serum over the 24 hour period. Results expressed as 
mean ± SEM, n=3 separate experiments with 3 replicate for each condition, * is p< 0.05. 
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Figure 2.4 High glucose increases B16BL6 cell migration.  B16BL6 cells were treated 
with DMEM media containing either high (4,500 mg/L) or low (1,000mg/L) glucose, and 
cell motility was determined using the wounding assay after 9 hrs. High glucose exposure 
increased the ability of B16BL6 cells to migrate. B) Representative pictures of cell 
motility and quantification of the assay results (mean ± SEM, n=3 separate experiments 
with 3 replicate for each condition, * is p< 0.05) 
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Figure 2.5 B16BL6 gene expression and MMP9 activity. B16F1 or B16BL6 cells were 
treated with DMEM, 10% FBS, 5% ob/ob serum or 5% control serum for 24 hrs as 
indicated and analyzed by qRT-PCR or Immunofluorescence microscopy. A) Metastatic 
B16BL6 cells have higher Snai1 and Twist mRNA levels than non-metastatic B16F1 
cells. Conversely, B16BL6 cells express less E-cadherin than B16F1 cells. B) B16BL6 
cells treated with 10% FBS express higher Snai1 mRNA levels than FBS-starved cells. 
C) Ob/ob serum increased Snai1, Twist, and Matrix Metalloproteinase 9 (MMP9) mRNA 
levels. Conversely, ob/ob serum decreased the expression of the metastasis suppressor 
Kiss1 (mean ± SEM, n=4 separate experiments with 3 replicates for each condition, * is 
p< 0.05). D) Nuclear expression of Snai1 and localization of E-cadherin in B16BL6 cells 
(n=3). White arrow indicates cell-cell junction. E) Total E-cadherin expression in 
B16BL6 cells. F) Active MMP9 secreted by B16BL6 cells (n=3). 
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Figure 2.6 Effects of obesity factors on Snai1, Kiss1, and MMP9 expression.  
B16BL6 cells were treated with resistin (100ng/mL), insulin (1 and 6ng/mL) and TNF-α 
(1ng/mL) for 24 hrs unless indicated otherwise, to determine the expression of Snai1, 
Kiss1, and MMP9 through qRT-PCR. A) Effects of resistin on Snai1, MMP9 and Kiss1 
mRNA expression. B) Effects of insulin on Snai1, MMP9 and Kiss1 mRNA expression. 
C) Effects of TNF-α (1ng/mL) on Kiss1 mRNA expression. (mean ± SEM, n=3 separate 
experiments with 3 replicate for each condition, * is p< 0.05) 
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Figure 2.7 Proposed mechanism by which ob/ob serum increases the metastatic 
ability of B16BL6 melanoma. Obesity is characterized by high systemic levels of 
glucose, IL-6, and TNF-α. These factors may increase the mesenchymal phenotype by 
increasing the expression of Snai1, Twist, and MMP9, and thereby increase the invasive 
ability of B16BL6 melanoma cells. Moreover, such pro-cancerous environment may 
simultaneously decrease the expression of metastasis suppressor such as Kiss1, and thus 
further increase the metastatic phenotype of melanoma. 
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CHAPTER 3: ADIPOCYTES PROMOTE B16BL6 MELANOMA CELL INVASION 
AND THE EPITHELIAL-TO-MESENCHYMAL TRANSITION 
ABSTRACT  
Epidemiological and animal studies suggest that obesity increases the metastatic ability 
of malignant melanoma, though the mechanism is not known.  In the present study, we 
assessed the ability of 3T3L1 adipocytes to modulate B16BL6 melanoma cell invasion 
and the Epithelial-to-Mesenchymal Transition (EMT).  For this purpose, we induced the 
differentiation of 3T3L1 fibroblasts to adipocytes.  Then, we collected the cell culture 
media from both fibroblasts and adipocytes and determined their effect on the invasive 
ability and EMT gene expression of B16BL6 melanoma cells.  Results showed that 
adipocyte media increased B16BL6 cell invasiveness.  The higher invasive ability of 
B16BL6 melanoma cells was associated with increased expression of EMT genes such as 
Snai1, MMP9, Twist, and Vimentin.  Additionally, the expression levels of the cell-to-
cell adhesion protein E-cadherin and the metastasis suppressor gene Kiss1 were down-
regulated in these B16BL6 cells.  Also, adipocytes had high levels of the pro-
inflammatory cytokine Interleukin 6 (IL-6).  Treatment of B16BL6 cells with IL-6 
elicited effects similar to those observed with the adipocyte media; IL-6 was able to 
promote the invasive ability of B16BL6 melanoma cells, increase the expression of 
Snai1, and decrease Kiss1 expression compared to FBS-starved cells. IL-6 neutralization 
of the adipocyte media, however, did not have a visible effect on the adipocyte media-
induced invasion and Snai1 staining. In summary, adipocytes may secrete factors besides 
IL-6 that are important in increasing the invasive ability of B16BL6 melanoma cells by 
promoting EMT and decreasing the expression of genes such as E-cadherin and Kiss1. 
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INTRODUCTION  
Studies suggest that obesity increases the ability of malignant melanoma to metastasize 
(38, 40). Dennis et al. showed that obesity increased the risk of developing subcutaneous 
melanoma (37); furthermore, Samanic et al. demonstrated that obesity increased the risk 
of developing malignant melanoma (38).  In animal studies, Mori et al. showed that 
obesity promotes B16BL6 melanoma pulmonary metastasis (40).  Approximately 60% 
of the U.S. population is considered overweight or obese (146).  In obesity, fat cells 
produce inflammatory factors such as the cytokine Interleukin 6 (IL-6), which can lead to 
the development of a low-grade inflammation environment (47).  This inflammation 
environment has been hypothesized to increase cancer risk (147). 
The microenvironment surrounding the melanoma cells may indeed play an 
important role in obesity’s ability to promote metastasis.  Obesity may cause a pro-
cancerous microenvironment by providing growth factors and inflammatory factors that 
can increase metastasis (41). Some of the cells that comprise the cancer 
microenvironment include cancer-associated fibroblasts (FACs), macrophages (TAMs), 
and adipocytes (44-46).  These cancer-associated cells are capable of secreting factors 
that can impact cancer metastasis (148, 149). 
Our present objective was to determine if adipocyte-conditioned media promotes 
melanoma metastasis. For this purpose, we differentiated 3T3L1 fibroblasts into 
adipocytes, and then investigated the effect of 3T3L1 fibroblast and adipocyte media on 
B16BL6 melanoma cell invasiveness and the Epithelial-to-Mesenchymal Transition 
(EMT).  EMT is a critical cellular program for the initiation of the metastatic cascade 
(150).  Cancer cells with a mesenchymal phenotype have a higher propensity to 
metastasize than those with an epithelial phenotype (125).  Increased expression of the 
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transcription factors Snai1 and Twist are associated with increased EMT and increased 
ability of cancer cells to migrate, invade, and metastasize (48, 126).   
The aberrant expression of Snai1 and Twist can lead to a significant loss of cell-
to-cell adhesion proteins such as E-cadherin (128).  The mesenchymal phenotype is also 
associated with high expression of Matrix Metalloproteinases (MMPs) such as MMP9 
that can degrade the extracellular matrix (ECM) and allow the cancer cells to metastasize 
(129).  Thus, inflammatory cytokines such as IL-6 may promote EMT and increase the 
metastatic ability of melanoma cells. Furthermore, increased EMT has been associated 
with decreased expression of various metastasis suppressors (56).  Metastasis suppressor 
genes encode proteins that have the ability to inhibit the establishment of metastases 
(130).  Metastasis suppressor genes such as Kiss1 can inhibit the metastatic ability of 
melanomas (131).  Thus, it is feasible that adipocytes secrete factors that promote the 
metastatic ability of melanomas by increasing the expression of pro-metastatic EMT 
genes and by decreasing the expression of metastasis suppressors such as Kiss1.  
In the present study, we showed that adipocyte media increased B16BL6 cell 
migration and invasion.  Increased motility and invasion are hallmarks of metastasis and 
rely on the induction of EMT (68).  We further showed that adipocyte media increased 
the expression of EMT-associated genes such as Snai1, Twist, MMP9, and Vimentin, 
while it decreased the expression of E-cadherin and Kiss1 in B16BL6 cells. Lastly, we 
showed that the cytokine IL-6, which was increased in adipocytes, could also promote 
B16BL6 cell invasion, increase Snai1 expression, and decrease Kiss1 expression to levels 
comparable to the adipocyte media.  Neutralization of IL-6 in the adipocyte media, 
however, did not nullify the media’s promotive effects on cell invasion and Snai1 
expression.  Therefore, our results suggest that the adipocyte media may increase the 
metastatic ability of melanoma cells through other factors besides IL-6. Further studies 
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will need to be performed to confirm the role of IL-6 in the metastatic ability of 
melanomas. 
 
METHODS AND PROCEDURES 
Cancer cells and cell culture reagents  
B16BL6 melanoma cells were kindly provided by Dr. Isaiah J. Fidler, University of 
Texas MD Anderson Cancer Center, Houston TX.  They were maintained in high glucose 
Dulbecco’s modified minimum essential medium (DMEM) (Invitrogen, Carlsbad, CA) 
containing 10% heat-inactivated fetal bovine serum (Invitrogen) and 1% antibiotic-
antimycotic solution (CellGro, Manassas, VA), and grown at 37°C in a humidified 
atmosphere of 5% CO2.  For cell culture studies, B16BL6 cells were treated with 5% 
adipocyte media, 5% fibroblast media, or control DMEM with no phenol red 
(Invitrogen).  Purified IL-6 was purchased and reconstituted in PBS containing 0.1% 
BSA to a concentration of 10ug/mL and stored in -80°C until used (R&D Systems, 
Minneapolis, MN). Cells were treated with 1ng/mL IL-6 in control DMEM for the IL-6 
treatments at the various time points.  
Differentiation of 3T3L1 fibroblasts to adipocytes  
To test the effect of 3T3L1 adipocytes on B16BL6 cell invasion and EMT gene 
expression, 3T3L1 fibroblasts were purchased from the American Type Culture 
Collection (ATCC, Chicago, IL; no. CL-173).  They were maintained in DMEM 
supplemented with 10% FBS until they were differentiated into adipocytes as described 
previously (151).  Adipocyte differentiation was confirmed through visual observation of 
lipid droplets as well as Oil Red O staining as previously described (152).  For collection 
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of fibroblast or adipocyte media, 3T3L1 cells were split into two equal plates.  For 
fibroblast-conditioned media, cells were allowed to proliferate until the plate was 70% 
confluent.  Cells were rinsed twice with PBS, and DMEM was subsequently added.  
After 24 hrs, the media was collected, centrifuged at 10,000 rpm for 10 mins at 4°C, and 
the supernatant was collected and stored at -80°C (Fibroblast Media).  The other plate 
was differentiated into adipocytes accordingly, and after full differentiation (day 14), 
adipocytes were rinsed twice with PBS, and DMEM was subsequently added.  After 24 
hrs, the media was collected, centrifuged at 10,000 rpm for 10 mins at 4°C, and then the 
supernatant was collected and stored at -80°C (Adipocyte Media).  These conditioned 
media were then used to determine their effect on B16BL6 melanoma migration and 
invasive ability as well as their ability to influence the EMT phenotype.  
IL-6 neutralization of adipocyte media  
Adipocyte media was thawed on ice before being incubated with 2ug/mL of IL-6 
antibodies (Ambion/Applied Biosystems, Austin, TX) on a rotary shaker for 4 hrs at 4°C. 
100uL of Protein A/G agarose slurry (Pierce Thermo Scientific, Waltham, MA) was 
added and subsequently incubated overnight at 4°C.  Then, the media was centrifuged at 
10,000rpm for 5 mins at 4°C to remove the beads.  The supernatant was collected and 
stored at -80°C.  This media was referred to as IL-6-neutralized adipocyte media 
throughout this manuscript. A decrease in IL-6 expression was confirmed with Western 
blot analysis before the media was used for subsequent assays.  
Wounding assay  
To determine the effect of adipocyte media on B16BL6 cell migration, we performed the 
wounding assay.  Cells were plated to 100% confluency and a scratch was drawn in the 
middle of the plate.  The decrease in gap distance was measured over time and quantified; 
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the larger the gap distance that remained after a given time point, the less the cells have 
migrated.  Briefly, B16BL6 cells were grown on a 24-well plate until they were 
confluent.  Then, cells were grown in FBS-free DMEM overnight.  The next day, wells 
were washed twice with PBS and a scratch was drawn on each well using a p200 pipette 
tip.  After two more washes with PBS to get rid of cell debris, the following cell culture 
media was added: 5% adipocyte media, 5% fibroblast media or control DMEM.  Each 
well was photographed at the time of treatment (0 hr) and after 16 hrs of incubation (16 
hr) at 40x. The difference in gap distance was measured (16 hr time point – 0 hr time 
point) to quantify cell motility. Each experiment was repeated three times with each 
group having 3 wells per experiment.  
Invasion assay  
The effect of adipocyte media on B16BL6 cell invasion was determined by the Boyden 
chamber invasion assay.  In this assay, the top chamber was previously coated with BD 
Matrigel
TM
 that is composed of various extracellular matrix proteins such as laminin and 
collagen (BD Biosciences, Franklin Lakes, NJ).  Cells were FBS-starved overnight, then 
rinsed with PBS before being trypsinized and counted by hemocytometry.  100,000 
cancer cells were placed in the top chamber in serum-free DMEM with
 
0.1% Bovine 
Serum Albumin (BSA).  The lower chamber was filled with DMEM (control), 5% 
adipocyte media, 5% IL-6 neutralized adipocyte media, 5% fibroblast media, or DMEM 
containing 1ng/mL IL-6.  Cells were allowed to invade from the top side towards the 
bottom side of each chamber for 28 hrs.  Cells that invaded to the bottom side were fixed 
and stained using Siemens Diff-Quick Stain Set (Siemens, Malvern, PA).  Stained cells 
were visualized and quantified by microscopy.  To determine the average number of cells 
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that migrated for each well, we counted 3 random fields in each well at 200x; each 
treatment had three individual wells.  Three separate experiments were carried out.  
Quantitative real-time PCR (qRT-PCR)  
To determine the effect of adipocyte media on the expression of several genes associated 
with EMT, qRT-PCR was performed.  Total RNA was collected from cells that were 
FBS-starved overnight and treated with control media, 5% fibroblast media, 5% 
adipocyte media, or 1ng/mL IL-6 for the stated amount of time.  RNA was extracted 
using an RNeasy Mini Kit according to the manufacturer’s instructions (Qiagen, 
Valencia, CA).  Reverse transcription was performed with the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA), using 1 g of RNA for 
each reaction.  Primers for 18S, Snai1, MMP9, Twist, Vimentin, E-cadherin, and Kiss1 
were purchased from Integrated DNA Technologies (IDT, Coralville, IA) and were as 
follows: 18S F: GCATGGCCGTTCTTAGTTGGTGGA, B: 
TCTCGGGTGGCTGAACG-CCA; Snai1 F: CACCTCCAGA-CCCACTCAGAT, B: 
CCTGAGTGGGGTGGGAGCTTCC; MMP9 F: GCCCACCGTCCTTTCTTGTTGGA, B: 
GGGAGAGGTGGTTTAGCCGGTG; Twist F: CCACGCTGCCCTCGGA-CAAG, B: 
CCAGGCCCCCTCCATCCTCC; Vimentin F: CCAGAGACCCCAGCGCTCCT, B: 
GCCGGAGCCACCGAACATCC; E-cadherin F: TTGAGGAGTTGAATGCTGAC, B: 
AGCTCGAACTTTCCAAGCAG; Kiss1 F: GCAAGCCTGGGTCTGCAGGG, B: CGACTGC-
GGGAGGCACACAG.   
 qRT-PCR was performed with a SYBR GreenER qPCR kit (Invitrogen) in a 
Mastercycler ep Realplex Real-time PCR thermocycler (Eppendorf North America, 
Hauppauge, NY).  The relative expression levels of target genes were normalized to the 
housekeeping 18S rRNA.  Amplification specificity was confirmed by melting curve 
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analysis.  Each gene was measured in quadruplicate, and the average ΔCt was taken from 
the 4 wells before fold change was calculated using the ΔΔCt method.  At least three 
separate experiments were carried out.  
Western blot analysis  
To determine the protein expression of IL-6 in 3T3L1 fibroblasts and 3T3L1 adipocytes, 
Western blot analysis was carried out on whole cell lysates.  3T3L1 fibroblasts and 
differentiated 3T3L1 adipocytes were washed twice with PBS before being lysed in 
300uL RIPA buffer (Thermo Scientific) supplemented with a protease inhibitor cocktail 
(Roche, South San Francisco, CA).  After 45 minute incubation on ice, cells were 
centrifuged at 10,000 rpm for 10 mins at 4°C.  The supernatant was collected and protein 
concentration was measured using the Bradford Assay.  100ug of protein was loaded and 
run on an SDS-PAGE gel at 100-150V for 1 hr.  The gel was subsequently transferred to 
a PMSF membrane, blocked in 5% milk, washed numerous times in TBST, and blotted 
with appropriate antibodies and HRP-conjugated secondary antibodies before incubation 
with ECL and film exposure.  Membranes were probed using primary antibody for IL-6 
(Abcam, Cambridge, UK; no.ab6672) and β-actin (Cell Signaling, Danvars, MA, no. 
4967L) and respective secondary antibodies (Cell Signaling, no. 7074; and Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, no. 2768).   
We also measured the protein expression of IL-6 Receptor α and Snai1 in 
B16BL6 cells as a response to the various treatments.  For this purpose, B16BL6 cells 
were grown to about 70% confluency in 10 cm
3
 plates.  Cells were rinsed with PBS and 
then FBS-starved overnight.  Then, cells were treated with control DMEM, 5% adipocyte 
media, 5% fibroblast media, or 1ng/mL IL-6 in DMEM.  After the various time-point 
treatments, cells were rinsed twice with PBS, trypsinized, and centrifuged at 10,000 rpm 
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for 5 mins at 4°C.  The supernatant was discarded, and the pellets were stored in -80°C 
overnight.  Total protein was collected and quantified as described above.  For Western 
blotting, 100ug of protein samples were loaded in each well, run, and transferred to a 
PMSF membrane before being probed for IL-6 Receptor α [Santa Cruz Biotechnology 
Inc., IL-6Rα (H-300), no. 13947], Snai1 (Abcam, no. 63371), and β-actin. 
Flow Cytometry  
B16BL6 cells were grown to 70% confluency in 6 cm
3
 plates.  Cells were rinsed with 
PBS and FBS-starved overnight.  Then, cells were treated with control DMEM, 5% 
adipocyte media, or 1ng/mL IL-6 in DMEM.  After the various time point treatments, 
cells were rinsed with PBS, trypsinized, and centrifuged at 10,000 rpm for 5 mins at 4°C.  
The supernatant was decanted and the pellet was subsequently vortexed thoroughly to 
make a single cell suspension.  Cells were resuspended in 1mL cold PBS.  Cells were 
subsequently added drop-wise into 2mL of cold 100% ethanol while vortexing and stored 
at -20°C for up to one week.  Then, 2mL of this solution containing the cells were 
centrifuged at 1,600 rpm for 4 mins at 4°C.  Cells were washed twice with PBS, then 
permeabilized with 0.1% triton-X100/PBS and treated with antibodies against Snai1 or 
Kiss1 (Santa Cruz Biotechnology Inc., no. sc-18134) and appropriate fluorescently-
conjugated secondary antibodies (Cell Signaling, no. 4412; and Abcam, no. ab6949) as 
recommended by the manufacturer before being subjected to flow cytometry.  Mean 
fluorescent intensity was used as a measure of protein expression. 
Immunofluorescence Microscopy 
Wax pencils were used to mark a closed circle on microscope coverslips.  B16BL6 cells 
were plated into the circles and allowed to attach for 24 hrs before being FBS-starved 
overnight.  They were subsequently treated with 5% adipocyte media, 5% IL-6 
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neutralized adipocyte media, 1ng/mL IL-6, or control DMEM for 24 hrs.  Cells were 
washed twice with PBS and fixed in 4% formalin/PBS for 10 mins.  Then, cells were 
subsequently washed twice with PBS before being stored in PBS at 4°C overnight.  The 
next day, cells were permeabilized with 0.1% Triton-X100/PBS and neutralized with 
100uM glycine/PBS before being treated with antibodies against Snai1 or Kiss1 and 
appropriate fluorescently-conjugated secondary antibodies (Cell Signaling and Abcam) as 
recommended by the manufacturer.  After three washes with 0.2% Tween20 in PBS, cells 
were counterstained with two drops of DAPI/antifade (Millipore) according to the 
manufacturer’s instructions for detection of cellular nuclei.  After 15 mins of incubation, 
coverslips were placed onto microscope slides and sealed with nail polish, and images 
were taken with the Zeiss Axiovert 200 M fluorescent microscope at UT Austin’s ICMB 
Core Facility.  Images of control and experimental cells were acquired under identical 
exposure conditions for comparative analysis. 
Statistical analysis 
Experiments were analyzed for significance using the independent Student’s t-test or 
One-way ANOVA in SPSS (PAWS version 18).  P-values < 0.05 were considered 
significant, and all data is represented as the mean ± SEM where appropriate. 
 
RESULTS 
Adipocyte media promotes B16BL6 cell motility and invasion 
We determined the effect of adipocyte media on B16BL6 cell motility and cell invasion.  
Results showed that adipocyte media promoted the migration and invasion of B16BL6 
cells to a higher degree than DMEM alone or fibroblast media (Figure 3.1A-B).  
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Adipocyte media affects EMT gene expression in B16BL6 cells 
To better understand the mechanism by which adipocyte media affects the invasive 
phenotype of B16BL6 cells, we determined the effect of adipocyte media on the 
expression of genes associated with the Epithelial-to-Mesenchymal Transition (EMT).  
Cancer cells with a more mesenchymal phenotype metastasize better than those with an 
epithelial phenotype (138).  The mesenchymal phenotype is associated with the 
expression of transcription factors such as Snai1 and Twist, MMPs such as MMP9, and 
the intermediate filament protein Vimentin (56, 139).  Results showed that adipocyte 
media increased the expression of Snai1, Twist, MMP9, and Vimentin in B16BL6 cells 
(Figure 3.2).  Adipocyte media also decreased the expression of the cell-to-cell adhesion 
marker E-cadherin in B16BL6 cells (Figure 3.2).  EMT has been associated with a 
decreased expression of various metastasis suppressor genes, including Kiss1 (56).  Our 
results are consistent with this finding, as we showed that the expression of Kiss1 was 
reduced by adipocyte media in B16BL6 cells (Figure 3.2). 
Effects of IL-6 treatment and IL-6 neutralization on B16BL6 cell invasion 
We measured the expression of the inflammatory marker IL-6 in both 3T3L1 
fibroblasts and 3T3L1 adipocytes.  The protein expression of IL-6 was higher in the 
3T3L1 adipocyte culture than in the 3T3L1 fibroblast culture (Figure 3.3A).  Thus, it is 
feasible that adipocytes promote the aggressiveness and EMT phenotype in B16BL6 
melanoma cells via IL-6.  In fact, we showed that adipocyte media increased the 
expression of the IL-6 Receptor α (IL-6Rα) in B16BL6 melanoma cells in a time-
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dependent manner that was not observed in fibroblast media-treated B16BL6 melanoma 
cells (Figure 3.3B).  In addition, we showed that direct treatment of B16BL6 melanoma 
cells with IL-6 also increased the expression of IL-6Rα (Figure 3.3C).  We next 
determined the ability of IL-6 to affect the invasive ability of B16BL6 melanoma cells.  
Results showed that the IL-6 treatment increased cell invasion to levels comparable to 
those induced by adipocyte media (Figure 3.3D-E).  To determine the role of IL-6 found 
in the cell culture media, we neutralized it using antibodies against IL-6, and then 
determined the effect of this IL-6-neutralized adipocyte media on B16BL6 invasion.  
Results showed that the neutralization of IL-6 did not significantly alter the ability of the 
adipocyte media to affect the invasive ability of B16BL6 cells (Figure 3.3D-E).  Though 
further studies are necessary to completely rule out the effect of IL-6 on B16BL6 cell 
invasiveness, our results currently suggest that IL-6 may not be a critical factor in this 
process, given the similar results from adipocyte media treatment and IL-6-neutralized 
adipocyte media treatment. 
Effects of IL-6 on the expression of Snai1 and Kiss1 in B16BL6 cells 
To determine if the effects of IL-6 on the expression of IL-6Rα correlated with changes 
in the expression of Snai1 and Kiss1, we measured both their mRNA and protein levels in 
B16BL6 cells.  Results showed that Snai1 mRNA and protein levels were modestly 
increased by the IL-6 treatment (Figure 3.4A, 3.4C).  This effect of IL-6 on Snai1 was 
also observed with adipocyte media, which increased the protein expression of Snai1 in a 
time-dependent manner (Figure 3.4B).  In contrast, fibroblast media did not affect the 
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expression of Snai1 in B16BL6 cells (data not shown).  We determined that adipocyte 
media and IL-6 treatments affected Snai1 nuclear levels.  For this purpose, we used 
immunofluorescence microscopy.  Results showed that Snai1 was increased in the 
nucleus of B16BL6 cells as a result of both adipocyte media and IL-6 treatments (Figure 
3.4D).  However, IL-6-neutralized adipocyte media also increased Snai1 nuclear staining 
to levels that were similar to those in adipocyte media-treated B16BL6 cells when 
compared to control FBS-starved B16BL6 cells (Figure 3.4D). Thus, though IL-6 by 
itself may increase Snai1 expression as previously observed by others in other cancers, 
our results suggest that other factors in the adipocyte media may be more important for 
Snai1 expression in B16BL6 cells (98, 99). 
As our results showed that both adipocyte media and IL-6 treatments increased 
the ability of B16BL6 cells to invade, we rationalized that these treatments may affect the 
expression of metastasis suppressor genes.  We chose to determine the effect of IL-6 
treatment on the expression of Kiss1 because it has been shown to be decreased during 
the EMT (56).  Results showed that the IL-6 treatment decreased Kiss1 mRNA and 
protein expression in a time-dependent manner (Figure 3.5A-B). Immunofluorescence 
microscopy experiments confirmed these results and showed that both IL-6 and adipocyte 
media treatments decrease Kiss1 expression (Figure 3.5C). 
DISCUSSION 
Our findings showed that adipocytes increase the malignancy of B16BL6 melanoma 
cells.  We showed that adipocyte media increased the ability of B16BL6 cells to migrate 
and invade.  These effects of adipocyte media on the malignant phenotype of melanoma 
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cells correlated with changes in EMT gene expression.  We showed that the expression of 
Snai1, Twist, MMP9, Vimentin, E-cadherin, and Kiss1 were modulated by adipocyte 
media.  Additionally, we showed that adipocytes expressed higher levels of the cytokine 
IL-6.  Moreover, treatment of B16BL6 with IL-6 elicited effects similar to those of 
adipocyte media on the ability of melanoma cells to invade.  The IL-6 treatment also 
increased the expression of Snai1 and decreased the expression of Kiss1 in B16BL6 cells.  
However, neutralization of IL-6 in the adipocyte media did not decrease the effects of 
adipocyte media on the invasive phenotype of B16BL6 cells and on the expression of 
Snai1.  Therefore, though IL-6 could have an observable effect on cell invasiveness and 
Snai1 expression when compared to FBS-starved B16BL6 cells, it may be an 
unnecessary component for the observed adipocyte media-induced effects. This suggests 
the existence of other factors in the adipocyte media that may have a much more 
significant impact on the expression of EMT-associated genes such as Snai1. 
Evidence by others suggests that the EMT plays an important role in the 
metastatic ability of cancer cells (150).  In particular, cancer cells that have acquired a 
mesenchymal phenotype metastasize more than those with an epithelial phenotype (125).  
The expression of Snai1 and Twist is highly correlated with the  mesenchymal phenotype 
(68). In fact, others have shown that the mesenchymal phenotype and metastatic ability of 
melanomas are increased with Snai1 and Twist overexpression (56, 60, 128).  This is 
pertinent to melanomas because those with an epithelial phenotype are less aggressive 
than those with a mesenchymal phenotype (54).  As cancer cells transition towards a 
mesenchymal phenotype, they often lose the expression of cell adhesion proteins that 
 56 
keep the cells anchored together such as E-cadherin (141).  In some cancers, both Snai1 
and Twist are thought to decrease the expression of E-cadherin (142, 143).  We showed 
that adipocyte media increased the expression of Snai1 and Twist, and correspondingly 
decreased the expression of E-cadherin.  Moreover, adipocyte media increased the 
expression of MMP9.  Others have shown that Snai1 can increase the expression of 
MMP9, a protein that can degrade the extracellular matrix (77).  The degradation of the 
extracellular matrix may allow cancer cells to escape into the blood or invade secondary 
tissues (78).  Therefore, adipocytes may promote EMT by affecting the expression of 
Snai1 and Twist, which subsequently affect E-cadherin and MMP9 expression levels, 
thus allowing melanoma cells to invade and establish metastases.  
Interestingly, EMT has been associated with decreased expression of the 
metastasis suppressor gene Kiss1 (145).  Kiss1 was originally discovered for its ability to 
suppress the metastatic ability of two human melanoma cell lines (103).  Studies suggest 
that one of the anti-metastatic functions of Kiss1 may be to decrease the expression of 
MMPs such as MMP9 (107).  This would contribute to the inhibition of B16BL6 cell 
invasion.  Others also show that Kiss1 is down-regulated in cancer cells that acquire a 
mesenchymal phenotype (145).  We found that treatment of B16BL6 melanoma cells 
with adipocyte media led to decreased expression of Kiss1.  Thus, adipocytes may 
simultaneously induce the expression of EMT genes and down-regulate the expression of 
Kiss1, which allows the melanoma cells to become more aggressive. 
It is feasible that adipocytes affect the malignant phenotype of melanomas via 
multiple factors, including the Transforming Growth Factor (TGF-β).  Others have shown 
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that TGF-β plays a crucial role in EMT (49, 153, 154). Interestingly, TGF-β is produced 
by 3T3L1 adipocytes as well (155, 156); moreover, it is highly expressed in the adipose 
tissue of obese individuals (156, 157).  Thus, it is possible that the TGF-β in the 
adipocyte media was also partly responsible for the increase in cell invasion and Snai1 
expression as others have already confirmed a positive relationship between TGF-β and 
Snai1 expression as well as cell invasiveness (154, 158). Therefore, the presence of TGF-
β may be part of the reason why IL-6 neutralization of the adipocyte media did not have 
an observable effect on the media’s ability to affect B16BL6 cells in our study even 
though IL-6 alone could elicit similar promotive effects from the B16BL6 cells. In 
conclusion, our results suggest that the adipocyte media may affect the malignancy of 
melanoma cells by promoting EMT and subsequently decreasing the expression of the 
metastasis suppressor Kiss1 independently of the presence of IL-6. 
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Figure 3.1 Adipocyte media increases B16BL6 cell invasion. B16BL6 cells were 
exposed to 5% adipocyte media, 5% fibroblast media, or control DMEM for the 
wounding and invasion assay.  A) In the wounding assay, B16BL6 cells were exposed to 
their respective media for 16 hrs, and distance migrated was calculated.  B) In the 
invasion assay, B16BL6 cells were exposed to their respective media for 28 hrs and 
number of cells that invaded was determined.  The data are representatives of three 
separate experiments, presented as ± SEM (* p<0.05). 
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Figure 3.2 Effects of adipocyte media on EMT gene expression in B16BL6 cells.  
Cells were treated with 5% adipocyte media or 5% control fibroblast media for 24 hrs.  
Adipocyte media increased Snai1, Matrix Metalloproteinase 9 (MMP9), Twist, and 
Vimentin mRNA levels.  Conversely, adipocyte media decreased the expression of E-
cadherin and the metastasis suppressor Kiss1.  Relative mRNA fold change was 
normalized to 18S rRNA and expressed as fold change over untreated controls.  The data 
are representative of at least three separate experiments, presented as ± SEM (* p<0.05). 
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Figure 3.3 IL-6 treatment and IL-6 neutralization on B16BL6 cell invasion.  A) IL-6 
protein expression was increased in 3T3L1 adipocytes compared to 3T3L1 fibroblasts as 
observed by Western blot analysis.  B) B16BL6 cells were exposed to 5% adipocyte 
media for the given time period, and IL-6Rα levels were measured by Western blot 
analysis.  C) B16BL6 cells were exposed to 1ng/mL IL-6 for the given time period, and 
IL-6Rα levels were measured by Western blot analysis.  D) B16BL6 cells were exposed 
to 1ng/mL IL-6, 5% adipocyte media, 5% IL-6 neutralized adipocyte media, or control 
DMEM for 28 hrs in the invasion assay.  The average number of cells that invaded when 
exposed to each treatment was calculated and quantified.  E) Representative pictures of 
fields used to quantify cell invasion.  The data are representative of at least three separate 
experiments and presented as ± SEM where appropriate (* p<0.05).
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Figure 3.4 The effect of IL-6 on Snai1 expression in B16BL6 cells.  B16BL6 cells 
were treated with 1ng/mL IL-6 for the stated time periods or as indicated. A) mRNA 
levels of Snai1 were increased at the time points, where the highest and significant 
change was observed at the 1 hour time point. B) B16BL6 cells were treated with 5% 
adipocyte media for 24 hrs.  Snai1 protein levels were modestly increased in a time 
dependent manner. C) Similarly, Snai1 protein levels were increased in a time dependent 
manner after the IL-6 treatment. D) Nuclear staining of Snai1 was increased in B16BL6 
cells treated with IL-6, 5% adipocyte media, or 5% IL-6 neutralized adipocyte media 
compared to control DMEM as observed by Immunofluorescence microscopy.  The data 
is representative of at least three separate experiments and presented as ± SEM where 
appropriate (* p< 0.05).
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Figure 3.5 IL-6 treatment decreased Kiss1 expression in B16BL6 cells.  B16BL6 cells 
were treated with 1ng/mL IL-6 for the stated time periods or as indicated.  A) mRNA 
levels of Kiss1 were decreased in a time-dependent manner.  B) Kiss1 protein expression 
was decreased after IL-6 treatment as observed by Flow Cytometry.  C) Kiss1 expression 
was decreased in B16BL6 cells treated with 5% adipocyte media and IL-6 for 24 hrs 
compared to control DMEM treatment as observed by Immunofluorescence microscopy.  
The data are representative of at least three separate experiments and presented as ± SEM 
where appropriate (* p< 0.05). 
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CHAPTER 4: OVERALL DISCUSSION AND FUTURE DIRECTIONS 
In this thesis, we investigated the effect of obesity on the expression of key genes 
associated with the Epithelial-to-Mesenchymal Transition (EMT) such as Snai1. We 
attempted to understand the effect of obesity on melanoma metastasis.  Epidemiological 
studies show that obesity is a risk factor for melanoma (37, 38). Others show that in 
ob/ob mice, a commonly used genetic model of obesity, B16BL6 experimental metastasis 
is increased compared to lean control mice (40).  We showed that systemic factors in 
ob/ob mice serum indeed increased the metastatic potential of B16BL6 cells in vitro; this 
increased invasion was accompanied by alterations in the expression profile of EMT 
markers – Snai1, Twist, MMP9, and metastasis suppressor Kiss1.   
Obesity is most often accompanied by increased amounts of adipocytes or fat 
cells, and the cytokine IL-6 has been shown to be elevated in obese individuals (88-90).  
In an effort to understand the role of adipocytes and specific obesity-related factors that 
may be important in obesity-induced melanoma metastasis, we proceeded to investigate 
the effects of adipocyte-conditioned media and IL-6 on B16BL6 cells.  IL-6 is also a 
serological marker for malignant melanoma (91), and some human melanoma cell lines 
endogenously produce IL-6 in an autocrine manner (97); these findings point to the 
possible importance of IL-6 in melanoma metastasis, but our study indicated that IL-6 
was not the most important factor in the adipocyte media-induced effects on B16BL6 
cells.  We showed that both adipocyte-conditioned media and exogenous IL-6 increased 
B16BL6 cell invasion and altered the expression of EMT markers Snai1, E-cadherin, and 
Kiss1.  However, neutralization of IL-6 in the adipocyte-conditioned media did not 
inhibit the effects of the adipocyte media on the invasiveness of the melanoma cells.  
Therefore, though further studies are necessary, this preliminarily suggests that IL-6 may 
 64 
not be a critical component of adipocyte media-induced cell invasiveness and that other 
factors are more important. There are a number of factors associated with obesity, 
including leptin, TGF-β, IL-6, IGF-1, TNF-α, that have been linked to cancer progression 
and EMT (58, 82, 98, 154, 159, 160); we also showed that Insulin, Resistin, and TNF-α 
modestly affected the expression of EMT genes such as Snai1, MMP9, and Kiss1.  Thus, 
it is feasible that obesity affects melanoma progression via a combination of multiple 
factors. 
The work in this thesis has not only added further evidence towards the 
importance of Snai1 and EMT in the melanoma metastatic cascade, but also 
demonstrated that EMT can be affected by external stimuli such as obesity.  It is 
important to continue to decipher other obesity-factors besides IL-6 that could have a 
more significant impact on Snai1 expression and EMT.  Furthermore, Snai1 function and 
activity are highly modulated by post-translational modifications such as phosphorylation 
and ubiquitination (48).  Thus, it is possible that obesity affects Snai1 by affecting its 
phosphorylation and ubiquitination (48).  This may be a possible future directions for 
these studies.  
Of interest, our results also showed that Kiss1 was affected by obesity.  We 
showed that obesity decreased Kiss1 expression in B16BL6 cells.  Others have shown 
that plasma Kisspeptin levels negatively correlates with insulin resistance and obesity 
(161).  It would be interesting to determine if increasing systemic levels of Kiss1 may 
inhibit the metastatic ability of melanomas.  Evidence suggests that high levels of Kiss1 
in people are feasible and may not lead to detrimental side effects.  For example, plasma 
kisspeptin levels are increased more than 7,000 times in pregnant women compared to 
non-pregnant women (162). This suggests that it may be physiologically possible to 
administer large concentrations of Kisspeptin intravenously to cancer patients.  Further 
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investigation, however, is still necessary to determine the effectiveness of exogenous 
Kiss1 administration and the appropriate concentrations required to affect cancer 
metastasis. 
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